CN118047872A - 抗cd30l抗体和其用途 - Google Patents

抗cd30l抗体和其用途 Download PDF

Info

Publication number
CN118047872A
CN118047872A CN202410189800.6A CN202410189800A CN118047872A CN 118047872 A CN118047872 A CN 118047872A CN 202410189800 A CN202410189800 A CN 202410189800A CN 118047872 A CN118047872 A CN 118047872A
Authority
CN
China
Prior art keywords
cdr
amino acid
acid sequence
seq
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410189800.6A
Other languages
English (en)
Chinese (zh)
Inventor
杰西-法拉·菲克特奥
马克·伦萧
乔汉·法兰森
奥立维尔·劳伦特
伯顿·巴奈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Falk Pharma GmbH
Prometheus Biosciences Inc
Original Assignee
Dr Falk Pharma GmbH
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma GmbH, Prometheus Biosciences Inc filed Critical Dr Falk Pharma GmbH
Publication of CN118047872A publication Critical patent/CN118047872A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202410189800.6A 2021-02-17 2022-02-16 抗cd30l抗体和其用途 Pending CN118047872A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17
US63/150,373 2021-02-17
PCT/US2022/016565 WO2022177963A1 (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof
CN202280028982.8A CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280028982.8A Division CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Publications (1)

Publication Number Publication Date
CN118047872A true CN118047872A (zh) 2024-05-17

Family

ID=82931610

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410189800.6A Pending CN118047872A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途
CN202280028982.8A Pending CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280028982.8A Pending CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Country Status (20)

Country Link
US (3) US20240254246A1 (https=)
EP (1) EP4294840A4 (https=)
JP (2) JP7559257B2 (https=)
KR (1) KR20230157356A (https=)
CN (2) CN118047872A (https=)
AR (1) AR124895A1 (https=)
AU (1) AU2022224561A1 (https=)
BR (1) BR112023016445A2 (https=)
CA (1) CA3208060A1 (https=)
CL (1) CL2023002393A1 (https=)
CO (1) CO2023011962A2 (https=)
CR (1) CR20230445A (https=)
EC (1) ECSP23070234A (https=)
GE (3) GEAP202416351A (https=)
IL (1) IL305146A (https=)
JO (1) JOP20230186A1 (https=)
MX (1) MX2023009621A (https=)
PE (1) PE20231680A1 (https=)
TW (1) TW202302637A (https=)
WO (1) WO2022177963A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
GEAP202416351A (en) * 2021-02-17 2024-02-12 Dr Falk Pharma Gmbh Anti-cd30l antibodies and uses thereof
WO2022271466A1 (en) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
CN119948058A (zh) * 2022-07-25 2025-05-06 普罗米修斯生物科学公司 抗cd30l抗体、其制剂及其用途
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
AU2024342871A1 (en) * 2023-09-12 2026-03-12 Amgen Inc. Anti-cd30l antibodies and uses thereof
WO2025075049A1 (ja) * 2023-10-03 2025-04-10 国立大学法人京都大学 ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005018571A2 (en) 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
JP2015502740A (ja) * 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
US9926373B2 (en) * 2012-04-27 2018-03-27 Novo Nordisk A/S Human CD30 ligand antigen binding proteins
EP2945865B1 (en) 2013-01-18 2019-01-09 LORD Corporation Active vibration control devices, systems, and methods
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
EP3405185A4 (en) 2016-01-19 2019-09-18 Thomas Blumenthal BIOMARKERS FOR DOWN SYNDROME AND USES THEREOF
PL3774897T3 (pl) * 2018-04-30 2024-01-29 Cedars-Sinai Medical Center Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
GEAP202416351A (en) 2021-02-17 2024-02-12 Dr Falk Pharma Gmbh Anti-cd30l antibodies and uses thereof

Also Published As

Publication number Publication date
BR112023016445A2 (pt) 2023-12-12
MX2023009621A (es) 2023-10-31
EP4294840A1 (en) 2023-12-27
CR20230445A (es) 2023-11-14
US12516126B2 (en) 2026-01-06
US11866505B2 (en) 2024-01-09
PE20231680A1 (es) 2023-10-19
ECSP23070234A (es) 2023-10-31
US20240254246A1 (en) 2024-08-01
AU2022224561A9 (en) 2023-10-05
JOP20230186A1 (ar) 2023-08-09
KR20230157356A (ko) 2023-11-16
CL2023002393A1 (es) 2024-03-22
CO2023011962A2 (es) 2023-09-29
US20240092923A1 (en) 2024-03-21
IL305146A (en) 2023-10-01
AR124895A1 (es) 2023-05-17
JP7559257B2 (ja) 2024-10-01
CA3208060A1 (en) 2022-08-25
GEAP202516710A (en) 2025-05-13
GEAP202416351A (en) 2024-02-12
JP2025004013A (ja) 2025-01-14
TW202302637A (zh) 2023-01-16
JP2024509746A (ja) 2024-03-05
WO2022177963A1 (en) 2022-08-25
CN117255802A (zh) 2023-12-19
GEP20257791B (en) 2025-09-10
EP4294840A4 (en) 2025-06-11
AU2022224561A1 (en) 2023-09-28
US20230060624A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
JP7559257B2 (ja) 抗ｃｄ３０ｌ抗体およびその使用
AU2020250266B2 (en) Antibodies comprising an ion concentration dependent antigenbinding domain, fc region variants, il-8-binding antibodies, and uses thereof
JP7749549B2 (ja) 抗ｔｓｌｐ抗体及びその使用
KR102844399B1 (ko) 항-cd3-결합 도메인 및 이를 포함하는 항체, 및 이를 생성하고 사용하는 방법
WO2019149269A1 (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
JP7419238B2 (ja) Ｐｄ１結合剤
JP2022540620A (ja) 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤
KR20250057935A (ko) Pdl1 표적화 항체 및 이의 사용 방법
KR20260039798A (ko) ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
TW202513584A (zh) Ｅｎｐｐ３及ｃｄ３結合劑及其使用方法
JP2024509191A (ja) 抗ｖｉｓｔａ構築物およびその使用
RU2807040C2 (ru) Связывающие домены антитела к cd3 и содержащие их антитела, а также способы их получения и применения
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
WO2023001025A1 (zh) Pd-l1抗体及其用途
HK40126939A (zh) 抗vista构建体及其用途
JP2023523760A (ja) 免疫グロブリン変異体
BR122024026051A2 (pt) Anticorpo ou polipeptídeo de ligação a antígeno, seu uso, composição, e artigo de fabricação

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination